Medifast (MED) Projected to Announce Earnings on Monday

Medifast (NYSE:MED) is expected to release its Q3 2026 results after the market closes on Monday, October 26th. Analysts expect Medifast to post earnings of ($0.35) per share and revenue of $71.30 million for the quarter. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, October 26, 2026 at 8:30 AM ET.

Medifast (NYSE:MED) last issued its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.37. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. The firm had revenue of $76.38 million for the quarter, compared to analysts’ expectations of $72.70 million. On average, analysts expect Medifast to post ($1.04) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Medifast Trading Down 2.5%

NYSE MED opened at $11.87 on Friday. Medifast has a 52 week low of $9.22 and a 52 week high of $13.45. The firm has a 50 day moving average of $11.95 and a two-hundred day moving average of $11.54.

Wall Street Analyst Weigh In

MED has been the topic of a number of analyst reports. Weiss Ratings upgraded shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a report on Monday, August 17th. Zacks Research raised shares of Medifast from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $12.00.

Insider Transactions at Medifast

In other Medifast news, Director Parsa Kiai bought 43,150 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were acquired at an average price of $12.26 per share, with a total value of $529,019.00. Following the transaction, the director owned 707,492 shares of the company’s stock, valued at approximately $8,673,851.92. The trade was a 6.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel Chard sold 9,545 shares of the firm’s stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $11.98, for a total value of $114,349.10. Following the sale, the director directly owned 140,153 shares in the company, valued at $1,679,032.94. This trade represents a 6.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders bought 119,966 shares of company stock worth $1,423,576. Company insiders own 3.70% of the company’s stock.

About Medifast

Medifast, Inc is a health and wellness company that provides weight-management and healthy-living products and services. Its primary brand, OPTAVIA, offers meal replacements, snacks, supplements and other nutrition products designed to support structured weight-management programs.

The company’s programs combine nutrition products with guidance from independent OPTAVIA Coaches. These coaches provide accountability, support and lifestyle guidance intended to help clients develop healthier eating and activity habits.

Medifast was founded in 1980 and is headquartered in Baltimore, Maryland.